SCHEMBL183868

SCHEMBL183868

CSc1nccc(-c2cnc3c(C(C)(C)O)cccn23)n1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK9 P45984 4/20 0.54
DYRK1A Q13627 4/20 0.43
DYRK3 O43781 1/20 0.43
DYRK2 Q92630 1/20 0.43
CCNA2 P20248 2/20 0.39
CDK2 P24941 2/20 0.39
CDK5 Q00535 2/20 0.39
CDK5R1 Q15078 2/20 0.39
DYRK1B Q9Y463 1/20 0.39
CSNK1E P49674 2/20 0.38
FLT3 P36888 4/20 0.38
TGFBR1 P36897 2/20 0.36
MAPK14 Q16539 2/20 0.36
MAPK13 O15264 1/20 0.36
MAPK12 P53778 1/20 0.36
MAPK11 Q15759 1/20 0.36
TGFBR2 P37173 1/20 0.35
KDM4E B2RXH2 1/20 0.34
ALDH1A1 P00352 1/20 0.34
HPGD P15428 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL182975 0.80 MAPK9 (0.52) MAPK9DYRK1AFLT3
SCHEMBL3552658 0.77 GABRA1 (0.40) MAPK9CDK2ALDH1A1HPGD
SCHEMBL3549513 0.76 DYRK1A (0.46) MAPK9DYRK1ADYRK3DYRK2CCNA2
SCHEMBL12272986 0.74 CSNK1E (0.58) DYRK1ADYRK3DYRK2CCNA2CDK2
SCHEMBL3557515 0.74 DYRK1A (0.65) MAPK9DYRK1ADYRK3DYRK2CCNA2
SCHEMBL183139 0.71 MAPK9 (0.79) MAPK9CDK2FLT3
SCHEMBL183662 0.71 MAPK9 (0.42) MAPK9KDM4EALDH1A1
SCHEMBL15344630 0.71 MAPK9 (1.00) MAPK9CDK2FLT3
SCHEMBL182632 0.71 MAPK9 (0.58) MAPK9DYRK1ACDK2FLT3
SCHEMBL7887171 0.71 MAPK9 (1.00) MAPK9CDK2FLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2401274-B1 IMIDAZO[1,2-A]PYRIDINES AS JNK MODULATORS HOFFMANN LA ROCHE (CH) 2014-10-22 EP disclosed
US-8569306-B2 JNK modulators HOFFMANN-LA ROCHE, INC. (US) 2013-10-29 US disclosed
EP-2401274-A1 IMIDAZO [1, 2 -A]PYRIDINES AS JNK MODULATORS F. Hoffmann-La Roche AG (CH) 2012-01-04 EP disclosed
US-20110306618-A1 JNK Modulators BUETTELMANN BERND (DE) 2011-12-15 US disclosed
WO-2010097335-A1 IMIDAZO [1, 2 -A] PYRIDINES AS JNK MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2010-09-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110306618-A1 JNK Modulators MAPK3, MAPK1, MAPK4 MAPK9 15/4885DYRK1A 174/4885DYRK3 96/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.